KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Weighted Average and Diluted) (2019 - 2025)

Rigel Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 10 years, most recently at $14.1 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 1640.74% year-over-year to $14.1; the TTM value through Dec 2025 reached $19.47, up 1886.73%, while the annual FY2025 figure was $19.48, 1867.68% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $14.1 at Rigel Pharmaceuticals, up from $1.46 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $14.1 in Q4 2025 and troughed at -$3.09 in Q4 2022.
  • A 5-year average of $0.81 and a median of -$0.08 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 2107.14% in 2022 and later surged 5566.67% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.14 in 2021, then tumbled by 2107.14% to -$3.09 in 2022, then surged by 101.62% to $0.05 in 2023, then skyrocketed by 1520.0% to $0.81 in 2024, then skyrocketed by 1640.74% to $14.1 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RIGL at $14.1 in Q4 2025, $1.46 in Q3 2025, and $3.28 in Q2 2025.